BBR has the ability to improve diabetic cardiomyopathy by increasing the expression of myocardial methionine sulfoxide reductase A (MsrA) and simultaneously inhibiting cardiac CaMKII oxidation (Sun et al., 2023). The gene discussed is MSRA; the disease is diabetic cardiomyopathy.